Loading...
OTCM
HRGN
Market cap40mUSD
Oct 08, Last price  
2.30USD
1D
0.00%
1Q
119.05%
Jan 2017
158.43%
IPO
9.00%
Name

Biostage Inc

Chart & performance

D1W1MN
OTCM:HRGN chart
P/E
—
P/S
57.44
EPS
—
Div yield, %
—
Shrs. gr., 5y
13.44%
Rev. gr., 5y
-18.35%
Revenues
704k
000022,00093,000118,00082,00000000000704,000
Net income
-7m
L-11.16%
-580,000-1,352,000-3,751,000-6,713,000-8,817,000-11,061,000-11,704,000-11,579,000-11,916,000-7,529,000-8,332,000-4,865,000-7,978,000-6,073,000-9,022,000-7,732,000-6,869,000
CFO
-4m
L-21.10%
-480,000-1,048,000-3,573,000-5,897,000-7,686,000-7,993,000-7,186,000-9,058,000-11,014,000-7,638,000-6,059,000-4,041,000-2,628,000-5,106,000-6,939,000-4,852,000-3,828,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Biostage, Inc. is a biotechnology enterprise dedicated to developing medical products aimed at curing patients suffering from cancers, injuries, and congenital defects within the gastrointestinal system and respiratory pathways. A primary focus for the company is the advancement of its Biostage Esophageal Implant, specifically designed to address esophageal cancer. Founded in 2009, the organization was formerly known as Harvard Apparatus Regenerative Technology, Inc. before rebranding as Biostage, Inc. in March 2016. Its corporate headquarters are located in Holliston, Massachusetts.

Key people

Hong Yu
President · since 2018
Peter Chakoutis
Principal Financial Officer, Principal Accounting Officer, Vice President - Finance · since 2020
Harout DerSimonian
Chief Scientific Officer · since 2016
Jason Jing Chen
Chairman of the Board · since 2018
David M. Green
Director · since 2015
Ting Li
Director · since 2018
James J. McGorry
Chief Executive Officer, Director · since 2017
James E Shmerling
Director · since 2018
Thomas H. Robinson
Independent Director · since 2012
URL
https://www.biostage.com/
IPO date
Oct 14, 2013
Employees
7
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT